Stereotaxis Inc

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stereotaxis anticipates revenue growth in 2023 with key innovations

Stereotaxis is poised for growth with key innovations nearing commercialization and a strong balance sheet.
Strategic collaborations, improved pipeline visibility, and targeted growth strategies position the company for future success.
Challenges in customer engagement and market penetration require proactive strategies to drive revenue growth.
Opportunities in SaaS business spin-off, IDN engagement, and product launches offer avenues for revenue expansion and market presence.

Stereotaxis Inc reports revenue decline but expects growth opportunities

Stereotaxis Inc reports revenue decline but expects growth with Genesis
Positive feedback on technology, regulatory progress, and innovation efforts
Challenges include catheter shortages and financial balancing act
Opportunities lie in increasing system orders and upcoming market releases

Stereotaxis Inc reports robust revenue growth and strategic collaborations

Stereotaxis Inc's Q2 2023 performance showcased strong revenue growth and strategic collaborations driving innovation.
While facing challenges like regulatory delays and cash flow issues, the company is focused on reducing cash usage and advancing key projects.
Opportunities lie in connectivity software releases, product development, and regulatory submissions, positioning Stereotaxis for future growth.

Stereotaxis reports Q3 revenue growth, faces operational challenges

Stereotaxis Inc saw modest revenue growth in Q3 driven by robotic system sales, but faced an operating loss.
Maintaining a strong financial position with no debt provides stability amidst operational challenges.
The company's focus on innovation and market strategies presents opportunities for future growth and product development.

Stereotaxis Inc reports Q4 revenue of $4.6M, focuses on innovation and regulatory progress

Stereotaxis Inc navigated challenges in Q4 2023 with a focus on innovation and strategic transformation. Strong financial position and confidence in regulatory processes position the company well for future growth. Revenue guidance for 2024 indicates potential for stable recurring revenue and increased system revenue.

Stereotaxis reports Q1 revenue growth, innovation progress, and APT acquisition

Stereotaxis Inc's Q1 2024 earnings call highlighted revenue growth, innovation progress, and the acquisition of APT. Despite challenges with recurring revenue and an operating loss, the company is optimistic about future growth driven by system backlog and new orders.

Stereotaxis Inc. reports Q2 loss, anticipates growth from GenesisX shipments

Stereotaxis Inc. faces challenges from reduced capital revenue but shows resilience with stable recurring revenue and a strong gross margin.
The company's strategic initiatives, including GenesisX and the APT acquisition, position it well for future growth and market expansion.
Analysts' inquiries reflect interest in key growth drivers like GenesisX, manufacturing scale-up, and macroeconomic influences on the business.
Overall, Stereotaxis Inc. aims for a stronger second half in 2024, leveraging new product offerings and revenue streams for improved financial performance.

Stereotaxis Inc reports revenue growth in Q3 2024 earnings

Stereotaxis Inc showed solid revenue growth in Q3 2024, driven by system and recurring revenue.
While facing challenges in operating expenses and profitability, the company has opportunities for growth.
Managing expenses and capitalizing on revenue potential could position Stereotaxis for improved financial performance.
The increase in cash reserves also provides a buffer for future investments and operations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Stereotaxis, Inc. (NYSE:STXS ) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants David Fischel - CEO & Chairman Kimberly Peery - CFO & Secretary Conference Call Participants Adam Maeder - Piper Sandler Neil Chatterji - B. Riley Securities Frank Takkinen - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Joshua Jennings - Cowen Javier Fonseca - Spartan Capital Operator Good morning.

Stereotaxis, Inc. (STXS) Q3 2022 Earnings Call Transcript

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates

ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022.

Stereotaxis Reports 2022 Third Quarter Financial Results

ST. LOUIS, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 third quarter on Thursday, November 10, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company's results and corporate developments.

Stereotaxis to Report Third Quarter Financial Results on November 10, 2022

ST. LOUIS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it was awarded the 2022 Innovation Award from the Office of the Mayor of St. Louis, Tishaura O. Jones. This recognition reflects Stereotaxis' regional leadership in advancing cutting-edge technologies with a positive impact on society.

Stereotaxis Receives St. Louis Mayor's Innovation Award for 2022

ST. LOUIS, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its attendance at the Sixth Annual International Meeting of the Society for Cardiac Robotic Navigation (SCRN) in Budapest from September 29-30.

International Meeting of the Society for Cardiac Robotic Navigation to Showcase Stereotaxis Technology and Its Clinical Value

ST. LOUIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Overland Park Regional Medical Center (OPRMC) is establishing its second robotic program for the treatment of heart rhythm disorders.

Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System

Stereotaxis, Inc. (NYSE:STXS ) Q2 2022 Earnings Conference Call August 9, 2022 10:00 AM ET Company Representatives David Fischel - Chairman, Chief Executive Officer Kim Peery - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Adam Maeder - Piper Sandler Neil Chatterji - B. Riley Alex Nowak - Craig-Hallum Capital Group Frank Takkinen - Lake Street Capital Markets Nathan Weinstein - Aegis Capital Javier Fonseca - Spartan Capital Operator Good morning!

Stereotaxis, Inc. (STXS) CEO David Fischel on Q2 2022 Results - Earnings Call Transcript

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 19.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Inc. (STXS) Reports Q2 Loss, Misses Revenue Estimates

ST. LOUIS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2022.

Stereotaxis Reports 2022 Second Quarter Financial Results

ST. LOUIS, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the significant enhancement of its commercial leadership team with the successful recruitment of two veterans of the medical device, surgical robotics and electrophysiology fields.

Industry Veterans Join Stereotaxis Commercial Leadership Team as Company Advances Robust Innovation Pipeline

ST. LOUIS, July 19, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 second quarter on Tuesday, August 9, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. ET that day to discuss the Company's results and corporate developments.

Stereotaxis to Report Second Quarter Financial Results on August 9, 2022

ST. LOUIS, July 11, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the CE Mark submission for its MAGiC™ catheter. The MAGiC catheter is a robotically navigated magnetic interventional ablation catheter for minimally invasive cardiac ablation procedures. Used in conjunction with Stereotaxis' robotic systems, the MAGiC catheter is designed to provide unparalleled catheter precision, stability and flexibility when diagnosing and treating cardiac arrhythmias.

Stereotaxis Announces CE Mark Submission for Robotically Navigated MAGiC Ablation Catheter

16 Peer-Reviewed Publications Highlight Clinical Value of Robotic Magnetic Navigation for Heart Rhythm Disorders 16 Peer-Reviewed Publications Highlight Clinical Value of Robotic Magnetic Navigation for Heart Rhythm Disorders

Journal of Atrial Fibrillation & Electrophysiology Publishes Special Issue Dedicated to Robotics in EP

Stereotaxis, Inc. (NYSE:STXS ) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Market Adam Maeder - Piper Sandler Alex Nowak - Craig-Hallum Capital Group Jason Wittes - Loop Capital Javier Fonseca - Spartan Capital Operator Good morning. Thank you for joining us for Stereotaxis' First Quarter 2022 Earnings Conference Call.

Stereotaxis, Inc. (STXS) CEO David Fischel on Q1 2022 Results - Earnings Call Transcript

ST. LOUIS, May 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2022.

Stereotaxis Reports 2022 First Quarter Financial Results

Denmark's only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis' advanced robotic technology Denmark's only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis' advanced robotic technology

Heart Centre Rigshospitalet Copenhagen Celebrates 5,000 Robotic Cardiac Ablation Procedures

Stereotaxis robotic technology now in use in 25 countries Stereotaxis robotic technology now in use in 25 countries

National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Heart Rhythm Disorders

Company joins Downtown North Urban Insight District in unique mixed-use space to accomodate growing surgical robotics business Company joins Downtown North Urban Insight District in unique mixed-use space to accomodate growing surgical robotics business

Stereotaxis Announces Grand Opening of New Global Headquarters in St. Louis

Solid Q4 beat overshadowed by prudent guidance that removes 4 "imminent" replacement system sales from FY2022 outlook. As per quarterly call, all have physician/administration support and remain “imminent”.

Stereotaxis: Replacement Cycle Timeline Drives Prudent Guidance, Creates Compelling Opportunity

Stereotaxis, Inc.'s (STXS) CEO David Fischel on Q4 2021 Results - Earnings Call Transcript

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Inc. (STXS) Reports Q4 Loss, Tops Revenue Estimates

ST. LOUIS, March 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Stereotaxis Reports 2021 Full Year Financial Results

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2021 fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company's results and corporate developments.

Stereotaxis to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

"Stereotaxis reminds me in many ways of Intuitive Surgical in our early years." - Executive VP & CMO of Intuitive Surgical and new Stereotaxis board member. Innovation Day showcased significant catalysts ahead including multiple regulatory milestones & commercial product launches; company well positioned to become the Intuitive Surgical of endovascular surgery.

News for Stereotaxis Inc Stock (STXS)